Dexcom (Nasdaq:DXCM) announced today that it launched its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) biosensor. The San Diego-based company made Stelo available for purchase — without prescription — at Stelo.com. Dexcom became the first company to receive FDA clearance for an OTC CGM when the FDA cleared Stelo in March. Abbott followed in June […]
Dexcom
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Tandem Diabetes Care integrates t:slim X2 with Dexcom CGMs in Canada
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its updated t:slim X2 insulin pump software with Dexcom (Nasdaq:DXCM) CGMs in Canada. San Diego-based Tandem now offers the t:slim X2 pump software with the Dexcom G6 and G7 continuous glucose monitors (CGMs). Health Canada authorized the combination, which already exists on the U.S. market, for […]
Dexcom stock falls on Q2 results that came up shy of ‘high standards’
Dexcom (Nasdaq:DXCM) (Nasdaq:DXCM) shares plummeted today on second-quarter results that came in mixed compared to the consensus forecast. Shares of DXCM fell more than 40% to $63.96 apiece in morning trading today. MassDevice‘s MedTech 100 Index was down slightly. The San Diego-based continuous glucose monitor (CGM) maker yesterday evening reported profits of $143.5 million. That […]
Report: Dexcom cuts California jobs in manufacturing, R&D shift
Dexcom (Nasdaq:DXCM) is reportedly relocating manufacturing operations amid a shift that eliminates more than 500 positions in San Diego. The San Diego Union-Tribune reported that the company plans to keep its headquarters in San Diego. However, its decision to move manufacturing to Arizona signals that Dexcom outgrew its facilities in San Diego. The move takes […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Dexcom CEO explains plans for Stelo CGM, G7 and beyond
Dexcom (Nasdaq:DXCM) CEO Kevin Sayer says the prospect of an over-the-counter CGM made him and other company leaders uneasy. When the company first began planning a glucose monitor for the type 2 diabetes population not using insulin, there were questions about reimbursement, the impact of GLP-1 drugs and other causes for concern. “It made us […]
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S. along with iPhone app
Insulet (Nasdaq:PODD) announced today that it began a full U.S. launch of Omnipod 5 with the Dexcom G7 continuous glucose monitor (CGM). The company also announced a series of launches and updates, including a limited release of the Omnipod 5 App for iPhone. Insulet also made Omnipod 5 available in France and launched the system […]
Dexcom launches G7 with Apple Watch integration in the U.S.
Dexcom (Nasdaq:DXCM) announced today that its G7 continuous glucose monitor (CGM) now connects directly to the Apple Watch in the U.S. San Diego-based Dexcom first announced the addition of this capability in March. The official launch makes G7 the first and only CGM available with a direct-to-Apple-Watch feature. It offers users the freedom and convenience […]
Dexcom earns CGM reimbursement in France for type 2 diabetes
Dexcom (Nasdaq:DXCM) announced today that its Dexcom ONE sensor received reimbursement for those with type 2 diabetes in France. The previous-generation Dexcom ONE sensor originally launched in France last fall. At that time, it covered patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy. Now, the company can […]
